| Vol. 11.33 – 4 September, 2020 |
| |
|
|
| Researchers showed in prostate cancer cells that LSD1 associated with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupted FOXA1 chromatin binding. [Nature Genetics] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists cultured hormone receptor-positive breast cancer and prostate cancer spheroids and patient-derived organoids in 3D extracellular matrices alone or together with bone marrow stromal cells. [Cancer Research] |
|
|
|
| Investigators found that phospholipase C epsilon (PLCÉ›) was highly expressed in prostate cancer samples, and was closely associated with androgen receptor signaling activities. [Cell Death & Disease] |
|
|
|
| The authors prepared multifunctional nanobubbles carrying indocyanine green and paclitaxel and studied their applications in ultrasound imaging of prostate cancer. [Journal of Nanobiotechnology] |
|
|
|
| Researchers investigated the novel multikinase PIM/PI3K/mTOR inhibitor, AUM302, versus a combination of the PIM inhibitor, AZD-1208, and the PI3K/mTOR inhibitor BEZ235 to determine their impact on mRNA and phosphoprotein expression. [Scientific Reports] |
|
|
|
| Scientists found microRNA-107 enhanced radiosensitivity by regulating granulin in prostate cancer cells. MiR-107 was downregulated and granulin was upregulated in response to ionizing radiation in prostate cancer cells. [Scientific Reports] |
|
|
|
| Researchers describe the establishment of immortalized normal prostate epithelial cell line models using CRISPR technology to inactivate the CDKN2A locus concomitantly with ectopic expression of an hTERT transgene. [Prostate Cancer and Prostatic Diseases] |
|
|
|
| To elucidate the influence of luteinizing hormone/choriogonadotropin receptor (LHCGR) on prostate cancer development, scientists investigated the presence and effects of LHCGR in prostate cancer. [PLoS One] |
|
|
|
|
| Scientists outline the present status quo for animal models of benign prostatic hyperplasia (BPH), comparing the pros and cons with respect to their ability to mimic the etiological, histological, and clinical hallmarks of BPH. [Prostate Cancer and Prostatic Diseases] |
|
|
|
|
| Telix Pharmaceuticals Limited announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform. [Telix Pharmaceuticals Limited] |
|
|
|
| Ibex Medical Analytics announces the first US deployment of its AI-powered solution for cancer detection in pathology, at the CorePlus Servicios ClÃnicos y Patológicos, LLC. [Ibex Medical Analytics] |
|
|
|
|
|
|
|
| Rutgers Cancer Institute of New Jersey – Rutgers, New Jersey, United States |
|
|
|
| University of Copenhagen – Copenhagen, Denmark |
|
|
|
| University of North Carolina at Chapel Hill – Chapel Hill, North Carolina, United States |
|
|
|
| Brigham and Women’s Hospital, Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| Cleveland Clinic – Cleveland, Ohio, United States |
|
|
|
|